H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharma (NASDAQ:LGND) on Monday, setting a price target of $229, which is approximately 177.74% above the present share price of $82.45.
Pantginis expects Ligand Pharma to post earnings per share (EPS) of $1.38 for the fourth quarter of 2020.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Ligand Pharma, with an average price target of $191.25.
The analysts price targets range from a high of $229 to a low of $146.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $41.42 million and a net profit of $7.1 million. The company's market cap is $1.33 billion.
According to TipRanks.com, H.C. Wainwright analyst Joseph Pantginis is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 17.6% and a 45.55% success rate.
Ligand Pharmaceuticals , Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.